BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vandendriessche A, Allegaert K, Cossey V, Naulaers G, Saegeman V, Smits A. Prospective validation of neonatal vancomycin dosing regimens is urgently needed. Curr Ther Res Clin Exp 2014;76:51-7. [PMID: 25061483 DOI: 10.1016/j.curtheres.2014.06.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Lestner JM, Hill LF, Heath PT, Sharland M. Vancomycin toxicity in neonates: a review of the evidence. Current Opinion in Infectious Diseases 2016;29:237-47. [DOI: 10.1097/qco.0000000000000263] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
2 Cies JJ, Moore WS, Nichols K, Knoderer CA, Carella DM, Chopra A. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support: . Pediatric Critical Care Medicine 2017;18:977-85. [DOI: 10.1097/pcc.0000000000001250] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
3 Petrie K, O'brien C, Bhushan S, Tonna A. Neonatal vancomycin trough level audit using British National Formulary for Children dosing. Arch Dis Child Fetal Neonatal Ed 2015;100:F278-9. [DOI: 10.1136/archdischild-2014-307725] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CMT, Spigarelli MG. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed 2016;101:F236-43. [DOI: 10.1136/archdischild-2015-308459] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
5 Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. Individualized Empiric Vancomycin Dosing in Neonates Using a Model-Based Approach. J Pediatric Infect Dis Soc 2019;8:97-104. [PMID: 29294072 DOI: 10.1093/jpids/pix109] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
6 Abduljalil K, Pan X, Pansari A, Jamei M, Johnson TN. A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building. Clin Pharmacokinet 2020;59:485-500. [PMID: 31583613 DOI: 10.1007/s40262-019-00825-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
7 Samardzic J, Smits A, Spriet I, Soldatovic I, Atkinson A, Bajcetic M, Van Den Anker JN, Allegaert K. Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates. Biomed Res Int 2016;2016:1974972. [PMID: 27635396 DOI: 10.1155/2016/1974972] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
8 Gwee A, Cranswick N, Donath SM, Hunt R, Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial. BMJ Open 2018;8:e022603. [PMID: 30391914 DOI: 10.1136/bmjopen-2018-022603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Janssen EJ, Välitalo PA, Allegaert K, de Cock RF, Simons SH, Sherwin CM, Mouton JW, van den Anker JN, Knibbe CA. Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother 2016;60:1013-21. [PMID: 26643337 DOI: 10.1128/AAC.01968-15] [Cited by in Crossref: 43] [Cited by in F6Publishing: 19] [Article Influence: 6.1] [Reference Citation Analysis]
10 Chung E, Sen J, Patel P, Seto W. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet 2021;60:985-1001. [PMID: 34002357 DOI: 10.1007/s40262-021-01027-9] [Reference Citation Analysis]
11 Dao K, Guidi M, André P, Giannoni E, Basterrechea S, Zhao W, Fuchs A, Pfister M, Buclin T, Csajka C. Optimisation of vancomycin exposure in neonates based on the best level of evidence. Pharmacological Research 2020;154:104278. [DOI: 10.1016/j.phrs.2019.104278] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Chung E, Lee SE, Abraham T, Saad NN, Gad A. Evaluation of vancomycin target trough attainment with published dosing regimens in the neonatal intensive care unit population. J Neonatal Perinatal Med 2019;12:21-7. [PMID: 30149480 DOI: 10.3233/NPM-182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Smits A, Pauwels S, Oyaert M, Peersman N, Spriet I, Saegeman V, Allegaert K. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis 2018;37:1503-10. [DOI: 10.1007/s10096-018-3277-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
14 Radu L, Bengry T, Akierman A, Alshaikh B, Yusuf K, Dersch-Mills D. Evolution of empiric vancomycin dosing in a neonatal population. J Perinatol 2018;38:1702-7. [PMID: 30341404 DOI: 10.1038/s41372-018-0251-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Elyasi S, Khalili H. Vancomycin dosing nomograms targeting high serum trough levels in different populations: pros and cons. Eur J Clin Pharmacol 2016;72:777-88. [PMID: 27117446 DOI: 10.1007/s00228-016-2063-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
16 Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert Opin Drug Metab Toxicol 2016;12:367-75. [PMID: 26817821 DOI: 10.1517/17425255.2016.1147559] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
17 Al-obaidy SSM, Halbus AF, Greenway GM, Paunov VN. Boosting the antimicrobial action of vancomycin formulated in shellac nanoparticles of dual-surface functionality. J Mater Chem B 2019;7:3119-33. [DOI: 10.1039/c8tb03102a] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
18 Monteiro JF, Hahn SR, Gonçalves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect 2018;6:e00420. [PMID: 30156005 DOI: 10.1002/prp2.420] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
19 Dawoud TH, Khan N, Afzal U, Varghese N, Rahmani A, Abu-Sa'da O. Assessment of initial vancomycin trough levels and risk factors of vancomycin-induced nephrotoxicity in neonates. Eur J Hosp Pharm 2022;29:44-9. [PMID: 34930794 DOI: 10.1136/ejhpharm-2019-002181] [Reference Citation Analysis]
20 Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer A. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther 2015;4:187-98. [PMID: 25998107 DOI: 10.1007/s40121-015-0067-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
21 Olafuyi O, Abbasi MY, Allegaert K. Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates-The impact of metabolising enzyme ontogeny and reduced cardiac output. Biopharm Drug Dispos 2021;42:401-17. [PMID: 34407204 DOI: 10.1002/bdd.2301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 van Groen BD, Pilla Reddy V, Badée J, Olivares-Morales A, Johnson TN, Nicolaï J, Annaert P, Smits A, de Wildt SN, Knibbe CAJ, de Zwart L. Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. Clin Transl Sci 2021;14:29-35. [PMID: 32702198 DOI: 10.1111/cts.12843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Pokorná P, Šíma M, Černá O, Allegaert K, Tibboel D, Slanař O. Actual body weight-based vancomycin dosing in neonates. J Chemother 2019;31:307-12. [PMID: 30983533 DOI: 10.1080/1120009X.2019.1599574] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
24 Wilbaux M, Fuchs A, Samardzic J, Rodieux F, Csajka C, Allegaert K, van den Anker JN, Pfister M. Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates. J Clin Pharmacol 2016;56:909-35. [PMID: 26766774 DOI: 10.1002/jcph.705] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]